GSK's Synflorix: closer to a different market place?
Published 28th January 2009
Recently the EU Committee For Medicinal Products for Human Use (CHMP) adopted a positive opinion to recommend a marketing authorisation for GSK's new pneumococcal vaccine, Synflorix. The vaccine will compete in a fiercely competitive market dominated by Wyeth (PCV-7). With the recent Pfizer news, GSK are no doubt hoping the acquisition may affect an optimum PCV-13 launch. They also have longer-terms plans for pneumococcal vaccines.
PREMIUMThis article is available only to VacZine Analytics clients or can be purchased for delivery.